Evidence map›Paper›PMID 30323636›Full record

ArticleClinicoEconomics and outcomes research : CEOR2018

Comparison of real-world clinical and economic outcomes between the ThermoCool

Larry Chinitz, Laura J Goldstein, Andrea Barnow, Sonia Maccioni, Mehmet Daskiran, Iftekhar Kalsekar, Rahul Khanna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Larry ChinitzNYU Langone Health, New York, NY, USA.
Laura J GoldsteinJohnson & Johnson Medical Devices, Irvine, CA, USA.
Andrea BarnowJohnson & Johnson Medical Devices, Irvine, CA, USA.
Sonia MaccioniJohnson & Johnson Medical Devices, Irvine, CA, USA.
Mehmet DaskiranJanssen, Raritan, NJ, USA.
Iftekhar KalsekarJohnson & Johnson Medical Device Epidemiology, New Brunswick, NJ, USA, rkhann14@its.jnj.com.
Rahul KhannaJohnson & Johnson Medical Device Epidemiology, New Brunswick, NJ, USA, rkhann14@its.jnj.com.
Johnson & Johnson (United States) · USJanssen (United States) · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study evaluated the real-world clinical and economic outcomes associated with the use of the ThermoCool

methodsAdults with AF who underwent catheter ablation between January 1, 2013, and December 31, 2016, in a hospital outpatient setting were identified from the Premier Healthcare Database. Using a search strategy of hospital-charge descriptors, patients were classified into two mutually exclusive groups: ThermoCool

resultsThere were 1,014 and 463 patients in the ThermoCool

conclusionsUsing the ThermoCool

Indexed as

atrial fibrillationirrigated-tip catheterradiofrequency ablationThermoCool® catheterThermoCool® Surround Flow catheter

Identifiers

PMID30323636
PMCPMC6181087
OpenAlexW2894801512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.